Details of the Drug

General Information of Drug (ID: DMWYMJN)

Drug Name
ALN-CC5
Indication
Disease Entry ICD 11 Status REF
Haemolytic uraemic syndrome 3A21.2 Phase 2 [1]
Drug Type
Antisense oligonucleotide
Cross-matching ID
TTD ID
DHTN76

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C5 messenger RNA (C5 mRNA) TT2LJRF CO5_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03303313) A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome. U.S. National Institutes of Health.
2 Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Mol Ther Methods Clin Dev. 2019 May 10;13:484-492.